四面体框架基于核酸的小干扰RNA向受体,用于高级甘化终端产品,用于糖尿病并发症的治疗
Zhengwen Cai1, Yong Li1, Long Bai2
1State Key Laboratory of Oral Diseases, National Center for Stomatology, National Clinical Research Center for Oral Diseases, West China Hospital of Stomatology, Sichuan University, Chengdu, Sichuan 610041, China.
ACS nano
|September 26, 2023
概括
一种新奇的纳米药物,Tsi,针对先进糖化终产品 (RAGE) 的受体来减少炎症和细胞死亡,为糖尿病并发症提供了一种新的治疗方法.
科学领域:
- 生物医学工程 生物医学工程
- 纳米医学是一种纳米医学.
- 分子生物学分子生物学
背景情况:
- 糖尿病并发症会影响多个器官,由高级糖化终产物 (AGEs) 驱动.
- 由于高血糖和加工饮食,AGE会积累,通过AGE受体 (RAGE) 触发炎症和细胞死亡.
- 现有的治疗方法通常集中在高血糖症上,因此需要替代策略来治疗AGE引起的损害.
研究的目的:
- 开发一种新的纳米医疗系统,Tsi,用于针对RAGE并减轻AGE引起的并发症.
- 评估Tsi在降低RAGE表达和抑制下游炎症途径方面的有效性.
- 评估Tsi对巨细胞灭的影响及其对糖尿病并发症协同治疗的潜力.
主要方法:
- 开发一种与siRNA结合的四面体框架核酸 (TDN) 系统 (Tsi),具有增强的细胞膜透和血清稳定性.
- 在体外和体内评估Tsi降低RAGE表达的能力.
- 分析Tsi对NF-κB炎症途径,抗氧化功能和巨细胞中NLRP3/caspase-1热致死轴的影响.
主要成果:
- 它有效和持续地降低RAGE的表达,抑制AGE诱导的炎症.
- 齐抑制NF-κB通路,并表现出抗氧化特性.
- 齐通过NLRP3/caspase-1轴调节巨细胞灭,防止细胞死亡信号的传播和维持平衡.
结论:
- 齐纳米医疗系统通过向RAGE和AGE诱导的炎症,为糖尿病并发症提供了一个有前途的治疗策略.
- Tsi 证明了长期有效性,独立于降低血糖水平.
- 这种方法为糖尿病并发症和可能与年龄相关的疾病提供了一种新的治疗途径.
更多相关视频
08:15Author Spotlight: Network Pharmacology and Molecular Docking to Decipher the Action of Jiawei Shengjiang San Against Diabetic Kidney Disease
Published on: May 10, 2024
603
09:04Sequence-specific and Selective Recognition of Double-stranded RNAs over Single-stranded RNAs by Chemically Modified Peptide Nucleic Acids
Published on: September 21, 2017
9.6K
相关概念视频
02:30siRNA - Small Interfering RNAs
16.8K
Small interfering RNAs, or siRNAs, are short regulatory RNA molecules that can silence genes post-transcriptionally, as well as the transcriptional level in some cases. siRNAs are important for protecting cells against viral infections and silencing transposable genetic elements.
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the...
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the...
16.8K
02:15Experimental RNAi
6.2K
RNA interference (RNAi) is a cellular mechanism that inhibits gene expression by suppressing its transcription or activating the RNA degradation process. The mechanism was discovered by Andrew Fire and Craig Mello in 1998 in plants. Today, it is observed in almost all eukaryotes, including protozoa, flies, nematodes, insects, parasites, and mammals. This precise cellular mechanism of gene silencing has been developed into a technique that provides an efficient way to identify and determine the...
6.2K
01:23RNA Interference
26.1K
RNA interference (RNAi) is a process in which a small non-coding RNA molecule blocks the post-transcriptional expression of a gene by binding to its messenger RNA (mRNA) and preventing the protein from being translated.
This process occurs naturally in cells, often through the activity of genomically-encoded microRNAs. Researchers can take advantage of this mechanism by introducing synthetic RNAs to deactivate specific genes for research or therapeutic purposes. For example, RNAi could be used...
This process occurs naturally in cells, often through the activity of genomically-encoded microRNAs. Researchers can take advantage of this mechanism by introducing synthetic RNAs to deactivate specific genes for research or therapeutic purposes. For example, RNAi could be used...
26.1K
01:24Glucagon-like Receptor Agonists
348
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
348
01:27Transducer Mechanism: Enzyme-Linked Receptors
2.5K
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
2.5K
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
223
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
223